Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine
- PMID: 16930784
- DOI: 10.1016/j.vaccine.2006.07.029
Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine
Abstract
We evaluated the cost-effectiveness of rotavirus vaccination in Uzbekistan from the healthcare system and societal perspectives. Disease burden was estimated using national statistics on hospitalizations and deaths, and international estimates of under-five mortality. Without vaccination, the risk for rotavirus hospitalization by age 5 is 10 per 1000 children. Rotavirus hospitalizations cost US$ 406,000 annually, of which US$ 360,000 (89%) is for medical expenses and US$ 46,000 (11%) is for non-medical and indirect costs. Rotavirus mortality rate at 0.7 per 1000 derived from national data was three-fold lower than the same rate calculated from international estimates of under-five mortality. Rotavirus vaccination could reduce hospitalizations and deaths by 91% and avert US$ 370,000 in hospitalization costs alone. Vaccination would be cost-effective with vaccine prices in a range of US$ 2-25 per child. However, the cost-effectiveness is greatly influenced by mortality, vaccine price and vaccine efficacy.
Similar articles
-
Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.J Infect Dis. 2009 Nov 1;200 Suppl 1:S195-202. doi: 10.1086/605040. J Infect Dis. 2009. PMID: 19817600
-
Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.J Infect Dis. 2005 Nov 15;192(10):1720-6. doi: 10.1086/497339. Epub 2005 Oct 14. J Infect Dis. 2005. PMID: 16235169
-
Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.J Infect Dis. 2009 Nov 1;200 Suppl 1:S16-27. doi: 10.1086/605026. J Infect Dis. 2009. PMID: 19817595 Review.
-
Cost-effectiveness and potential impact of rotavirus vaccination in the United States.Pediatrics. 2007 Apr;119(4):684-97. doi: 10.1542/peds.2006-2876. Pediatrics. 2007. PMID: 17403839
-
Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines.J Infect Dis. 2009 Nov 1;200 Suppl 1:S1-8. doi: 10.1086/605061. J Infect Dis. 2009. PMID: 19817589 Review.
Cited by
-
Assessment of the Impact of the Rotavirus Vaccine Against Severe Rotaviral Diarrhea in Uzbekistan.J Epidemiol Glob Health. 2023 Sep;13(3):476-484. doi: 10.1007/s44197-023-00126-z. Epub 2023 Jun 10. J Epidemiol Glob Health. 2023. PMID: 37300641 Free PMC article.
-
Rotavirus vaccine effectiveness and impact in Uzbekistan, the first country to introduce in central Asia.Hum Vaccin Immunother. 2021 Feb 1;17(2):503-509. doi: 10.1080/21645515.2020.1776034. Epub 2020 Aug 5. Hum Vaccin Immunother. 2021. PMID: 32755429 Free PMC article.
-
Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries.Open Forum Infect Dis. 2019 Mar 8;6(4):ofz117. doi: 10.1093/ofid/ofz117. eCollection 2019 Apr. Open Forum Infect Dis. 2019. PMID: 31049363 Free PMC article.
-
Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries.Cost Eff Resour Alloc. 2018 May 18;16:18. doi: 10.1186/s12962-018-0102-2. eCollection 2018. Cost Eff Resour Alloc. 2018. PMID: 29796012 Free PMC article. Review.
-
Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh.Hum Vaccin Immunother. 2018 Jan 2;14(1):189-198. doi: 10.1080/21645515.2017.1356962. Epub 2017 Dec 12. Hum Vaccin Immunother. 2018. PMID: 29099653 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical